Detailed Selling Lead Description

Evidence supporting the effectiveness of glatiramer acetate in decreasing the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis (RR MS) derives from two placebo-controlled trials, both of which used a glatiramer acetate dose of 20 mg/day. (No other dose or dosing regimen has been studied in placebo-controlled trials of RR MS).[2] A comparative trial of the approved 20 mg dose and the 40 mg dose showed no significant difference in efficacy between these doses[3].